Singapore HSA's 2026 Medical Device Grouping Guidance: Key Changes in GN-12-1-R3

Singapore's Health Sciences Authority (HSA) released its updated guidance on medical device grouping, GN-12-1-R3, on June 2, 2026. This episode provides a detailed analysis of the key changes, including stricter criteria for device families, new requirements for systems and procedure packs, and the direct impact on manufacturers' registration strategies, costs, and timelines in Singapore. We outline the mandatory effective dates and provide practical steps for regulatory teams to ensure compliance with the new rules. Key Questions: - What are the most significant changes in Singapore's new GN-12-1-R3 guidance? - How do the updated device family criteria affect our submission strategy? - Will our existing product groupings be accepted for future renewals? - What are the new rules for grouping systems and procedure packs in Singapore? - How will these changes impact registration costs and timelines? - When does this new HSA guidance become mandatory for submissions? - What immediate actions should our regulatory team take to adapt? - How does this guidance affect IVD manufacturers specifically? Sources: - https://www.hsa.gov.sg/medical-devices/guidance-documents How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like Singapore's updated HSA requirements. Our local experts and advanced AI tools streamline the development of regulatory strategies and the compilation of technical dossiers, ensuring your submissions are compliant and efficient. By leveraging our global representation network, we act as your local partner to manage the entire registration process, helping you get to market faster. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI regulatory tools and global device database at https://pureglobal.ai.